Closing

Do GLP-1 receptor agonists improve liver & MASLD versus placebo?

Mostly studied in type 2 & unspecified diabetes. Also asked against other treatments.

Mechanistic model availableWhy does fat build up in the liver in type 2 diabetes?See where the mechanism fails, how this treatment's effect is predicted and validated against held-out trials, and the decisive experiments that remain. →

Where the evidence stands

Doubtful. So far, no trial evidence yet.

NoUnsureYes
Belief
0.25 (range 0.10–0.70)
Trials for
0
Trials against
0
Inconclusive
3

Already under way

The evidence so far

Registered trials
125
With posted results
34
Published papers
6

Of 7 decided analyses: 0 favor glp-1 receptor agonists, 5 find no difference, 2 favor the comparator.

Papers

Trials

See every trial in the evidence map →